Poster and Platform Presentations by ADMDC Members
Click on the sign to list the poster and platform presentations by year. Then click on the link to view that presentation.
- A study to assess the safety, tolerability, and effectiveness of nuedexta (dextromethorphan 20 mg/quinidine 10 mg) in the treatment of pseudobulbar affect (PBA) [PRISM II].
- A simple method for enhancing prediction of longitudinal decline in instrumental activities of daily living in Alzheimer's patients.
- Improving predictive validity of the Clinical Dementia Rating Scale for functional outcomes.
2013 Alzheimer's Association International Conference (AAIC)
(July 13-18, 2013)
American Academy of Neurology (AAN)
65th Annual Meeting in San Diego, Calif.
(March 16-23, 2013)
International Neuropsychological Society (INS)
41st Annual Meeting in Montreal, Waikoloa, Hawaii
(Feb. 6-9, 2013)
- Mexican American normative references on tasks of memory and language: The Texas Mexican American normative studies.
- Normative data for Mexican American on tasks of executive and physiometric functions: The Texas Mexican American normative studies.
- Normative performance on the RBANS in a multi-ethnic bilingual cohort: The Texas Mexican American normative studies.
- Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease.
- Premorbid IQ and intrinsic progression rate explain substantial variance in observed progression of Alzheimer's disease (AD) on multiple measures.
- Factors influencing time to nursing home placement in persons with probable Alzheimer's disease.
- Factors that influence long term care placement in an Alzheimer disease cohort.
- Dimebon in Alzheimer's disease: Summary and contract of three efficacy trials.
National Academy of Neuropsychology (NAN)
32nd Annual Meeting in Nashville, Tenn.
(Nov. 7-10, 2012)
American Neurological Association (ANA)
137th Annual Meeting in Boston, Mass.
(Oct. 7-9, 2012)
Alzheimer's Association International Conference (AAIC)
Annual Meeting in Vancouver, British Columbia, Canada
(July 14-19, 2012)
International Neuropsychological Society (INS)
40th Annual Meeting in Montreal, Quebec, Canada
(Feb. 15-18, 2012)
- Serum granulocyte colony stimulating factor and Alzheimer's disease.
- The impact of depression on cognition varies by APOE4 status.
- Biomarkers associated with cardiovascular risk in the Texas Alzheimer's Disease Research and Care Consortium (TARCC) Cohort: LpPla2 and homocysteine.
- Inflammatory biomarkers in the Texas Alzheimer's Research and Care Consortium (TARCC) Cohort.
- Plasma sphingomyelin is associated with cognitive progression in Alzheimer's disease.
- Refinement and expansion of the Texas Alzheimer's research consortium serum-based diagnostic algorithm for Alzheimer's disease.
- A serum protein-based algorithm for the detection of Alzheimer's disease.
- Racial/ethnic group differences in the association of APOE ε4 genotype and visuospatial test performance in a non-demented sample.
- Factors that influence survival in Alzheimer's patients.
- The cognitive correlates of functional status: a new approach to dementia.
- Genome-wide association scan replication for biomarker endophenotypes of Alzheimer's disease.
- Developing and validating of diagnostic algorithm for Alzheimer's disease.
- Efficacy and safety of donepezil 23 mg/day in patients with moderate-to-severe Alzheimer's disease with concomitant memantine use.
- Differences in the association of peripheral insulin and cognitive function in non-diabetic ad cases and normal controls.
- Differential recall of nouns and verbs in patients with probable Alzheimer's disease (AD).
- Cognitive reserve as a moderator for the relationship between depression and cognitive functioning in Alzheimer's disease.
- Cortisol levels in Alzheimer's patients are related to premorbid functioning and rate of progression.
- An inflammatory endophenotype of Alzheimer's disease.
- Presence of cardiovascular disease is associated with slower cognitive decline in Alzheimer's disease in the absence of cerebrovascular pathology.
- A serum protein-based diagnostic algorithm for Alzheimer's disease.
- Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease.
- Association of genetic variation in the electron transport chain and Alzheimer's disease.
- Genome-wide association scan for biomarker endophenotypes of Alzheimer's disease.
- Plasticity of hippocampo-cortical network connectivity induced by midline thalamic (n. Reuniens) stimulation in the rat.
- How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis.
- Age at onset and pre- morbid IQ influence early progression rates in AD.
- Alzheimer's disease as descent into randomness: Evidence from category fluency testing.
- Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease.
- Interrater reliability between expert and nonexpert physicians in the assessment of amnestic MCI in the community setting.
- Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study.
- Mapping of Alzheimer disease stages using the MMSE: Effects of ethnicity and education.
- The effects of donepezil on Alzheimer's disease progression monitored by MRI.
- Persistent antidementia drug treatment and survival in an Alzheimer's disease (AD) cohort.
- The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype.
- Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting.
- Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results.
- Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study.
- Vitamin E use is associated with improved survival in an AD cohort.
- Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease.
- Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics.
- Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD).
- The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly.
- Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study.
- Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe).
- Predicting progression and survival in Alzheimer's disease.
- Is functional decline necessary for a diagnosis of Alzheimer's disease?
- Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes.
- Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease.
- Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients.
- Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease.
- Naming improvement with phonemic cues: Which Alzheimer's patients benefit most?
- Category-letter fluency discrepancies in healthy older adults: Normative data and reliability.
- Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.
- Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.
- Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis.
- Superior limbic keratoconjunctivitis in chronic ocular graft vs. Host disease.
- Mild cognitive impairment types and their outcomes.
- ADAS-Cog change rates in MMSE Strata relevant to clinical trials.
- Relationship of premorbid IQ and education to progression of Alzheimer's disease.
- Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day.
- Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
- Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits.
- Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients.
- Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary.
- Functional benefits of memantine treatment for patients with moderate to severe Alzhemier's disease.
- Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease.
- Anterior thalamus interaction with the retrosplenial cortex in the anaesthetized rat.
- Coherence analysis of anterior thalamic unit firing with retrosplenial cortical and hippocampal theta rhythm.
- Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia.
- Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease.
- How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses?
- Pathogenesis and treatment strategies for selected therapies under development.
- Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease.
- Survival in patients with dementia from a large multi ethnic population.
- Growth curve analysis of decline in instrumental activities of daily living in AD patients.
- Measurement invariance of theWAIS-R in AD among patients at higher versus lower levels of dementia severity.
- WAIS-R factor structure in AD: Comparison of alternative models and assessment of generalizability.
- A study of neural interactions within the limbic system using partial coherence and direct transfer functions analysis.
- Racial differences among patients with Alzheimer's disease from a large multi ethnic population.
- The cognitive benefits of galantamine are sustained for at least 24 months: Results of a long-term extension trial in Alzheimer's disease.
- Dynamical theta resonance between anterior thalamus and retrosplenial cortex in the anesthetized rat.
- Cholinesterase inhibitors: Benefits and limitations.
- Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study.
- Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden.
- Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety.
- Re-entrant theta activity in Papez circuit: Role of the anterior ventral nucleus of the thalamus.
- Patterns of neuronal activity in the median raphe during hippocampal theta rhythm in the anesthetized rat.
- Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study.
- Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration.
- Does ApoE4 correlate with MRI changes in Alzheimer's disease?
- Clinical benefits of donepezil: Results from a long-term phase III extension trial.
- Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials.
- Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients.
- The presence of APO E4 does not influence rate of decline in Alzheimer's disease.
- Current therapeutic standards in the treatment of Alzheimer's disease.
- Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance?
- Theta-rhythmic neuronal activity in anterior thalamic nuclei of the rat.
- Outcome measures in dementia trials-video CIBIC validity and reliability.
- Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study.
- Long lasting changes in cortical excitatory amino acid receptor levels and dopamine-induced behavior after neonatal excitotoxic lesions of the ventral hippocampus in rats.
- Prevalence of uncontrolled hypertension in a population of Alzheimer's patients.
- Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment.
- E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial.
- Pharmacologic evidence for autonomic psudomotor dysfunction in patients with Alzheimer's disease.
- Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials.
- A new clinical global rating scale for Alzheimer's clinical trials.
- Cortical NMDA receptor levels are increased in adult rats following neonatal excitotoxic lesions of the ventral hippocampus.
- Estrogen and psychomotor performance.
- A calculated measure to predict rate of progression in Alzheimer's disease.
- Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men.
- Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD).
- Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.
- Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.
- Dysfluency in the speech of AD patients.
- Literacy and cognition in northern Thailand.
- Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia.
- Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease.
- Correlates of asymmetric motor speed in Alzheimer's disease.
- Neuropsychological correlates of apraxia in Alzheimer's disease patients.
- Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia.
- Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery.
- Positive and negative psychiatric symptoms in Alzheimer's disease.
- The alien hand and related signs.
- Recurrent posterior-type aphasia associated with a seizure focus.
- Progressive nonfluent aphasia.
- Effects of stress management and dietary changes in treating ischemic heart disease.